TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Major patient;~* Having an indication for placement of PRG (percutaneous radiological gastrostomy);~* Patient hospitalized for a minimum of 24 hours post gastrostomy;~Non-inclusion criteria :~* Pregnant or lactating woman;~* Legal incapacity or limited legal capacity. Medical or psychological conditions which do not allow the subject to understand the study and sign the consent (art. L.1121-6, L.1121-7, L.1211-8, L.1211-9);~* Not knowing how to read and / or write French;~* Allergy and / or known hypersensitivity to lidocaine and / or ropivacaine or to other local anesthetics with amide bond or to one of the excipients;~* Recurrent porphyrias (genetic, hereditary diseases affecting the production of hemoglobin);~* Patient on beta blockers during the installation of PRG (Percutaneous Radiological Gastrostomy);~* Indication of gastrostomy button placement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Patients will receive Lidocaine alone during percutaneous gastrostomy under radiological guidance
- Lidocaine and Ropivacaine (Type: EXPERIMENTAL): Patients will receive Lidocaine and Ropivacaine during percutaneous gastrostomy under radiological guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Iron in Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Congestive heart failure~* At least 18 years of age~* Iron deficiency~* Dyspnea class II or III according to New York Heart Association~* Left-ventricular ejection fraction ≤ 45%~Exclusion Criteria:~* Known sensitivity to any of the products to be administered during dosing~* Immediate need of transfusion~* Patients presenting with an active infection~* Thalassaemia~* Other forms of microcytic anemia not caused by iron deficiency~* History of acquired iron overload~* Need for revascularization, ST-segment elevation myocardial infarction or Non-ST-segment elevation myocardial infarction during the past 3 months (at time of randomization)~* Women who are pregnant or of childbearing age and not using medically acceptable effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron (Type: ACTIVE_COMPARATOR): ferric carboxymaltose
- Placebo (Type: PLACEBO_COMPARATOR): Sodium chloride 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smokers or former smokers of at least 10 pack-years~* COPD demonstrated by forced spirometry with FEV1 \> 0,7 L, FEV1 post-BD \<60% and FEV1/FVC \< 70%~* Bronchodilator test performed at inclusion or no more than 6 months before inclusion should have been negative (increase in FEV1 \< 200 ml and 12%, 10 minutes after administration of 2 puffs of salbutamol~* Stable phase defined by clinical criteria of the attending investigator, but at least 6 weeks from the last exacerbation~* Informed consent~Exclusion Criteria:~* Patients receiving oral corticosteroids at any dose or another immunosuppressor~* Formal contraindication for sputum collection or impossibility to obtain a sample of sputum valid for analysis.~* Allergy to steroids or macrolides

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): standard of care
- 2 (Type: EXPERIMENTAL): azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
- 3 (Type: EXPERIMENTAL): inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of an Adaptive Treatment Algorithm for Post-op Thoracic Patients to Reduce the Length of Drainage

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a post operative air leak after 16 to 24 hours bigger than 50ml/min.~Exclusion Criteria:~* Patients with an empyema~* Patients with a spontaneous pneumothorax

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Digital chest tube (Type: None): All patients will be treated with the digital chest tube device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Delirium After Bone Marrow Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 or older~* Male or female~* Patients scheduled to undergo HSCT~* English speaking~Exclusion Criteria:~* Previous history of bipolar affective disorder~* On-going delirium~* History of substance abuse/dependence within 6 months prior to HSCT~* History of invasive melanoma. Patients with a history of basal cell carcinoma, melanoma in situ, or squamous cell carcinoma are permitted to enroll if the lesion(s) have been excised with negative margins~* History of medical/dermatological conditions that make skin especially sensitive to light,such as systemic lupus erythematosus (SLE) and/or porphyria~* Eye condition that makes eyes vulnerable to light damage~* Concomitant use of medications that increase sensitivity to sunlight, such as the herbal supplement St. John's Wort~* Established primary insomnia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Bright light therapy (Type: EXPERIMENTAL): 2500 Lux gaze directed every morning from 8 am until 8:30 am
- Sham light (Type: PLACEBO_COMPARATOR): \<1000 Lux gaze directed every morning from 8 am until 8:30 am

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure~* Meets the transplant criteria by the study site and both the recipient and donor have been accepted as candidates for standard of care living kidney donation and transplantation~* Patient is receiving a renal transplant only~* The crossmatch is negative between donor and recipient. An initial crossmatch will be performed prior to stem cell mobilization to determine if subject can proceed with the apheresis.~* Potential recipients who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving Granulocyte colony-stimulating factor (G-CSF) and agree to use reliable contraception for 1 year following FCRx infusion~* Potential donors who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving G-CSF~* No evidence of donor-specific antibody presently or historically~* Panel Reactive Antibody (PRA) less than or equal to 20~Note: The subjects do not need to be local residents in order to be eligible for this trial, but must be willing to reside in the area, or within a four-hour drive, for the first month of the protocol so that they can be monitored closely in the early post-transplant period.~Exclusion Criteria:~* Clinically active bacterial, fungal, viral or parasitic infection~* Pregnancy~* Clinical or serologic evidence of viral infection which would preclude the recipient from receiving a kidney transplant or FCRx infusion~* Previous radiation therapy at a dose which would preclude Total Body Irradiation (TBI)~* Positive crossmatch between donor and recipient~* Evidence for immunologic memory against donor~* Body Mass Index (BMI) \>35 or \<18~* Positive serologies for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Living Kidney Allograft (Type: EXPERIMENTAL): Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Sedation for Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject has cataract,~* subject older than 18 years,~* local anesthesia and sedation.~Exclusion Criteria:~* general anesthesia,~* history of consumption of sedatives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Vitiligo With Low-energy Visible Light Laser

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years old~* Have active or stable segmental vitiligo on the neck or face, acral vitiligo, or have undergone recent melanocyte-keratinocyte transplantation procedure (MKTP)~* Agree to abide by the Investigator's guidelines regarding photosensitizing drugs and photoprotection~* Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form~* Agree to follow and undergo all study-related procedures~Exclusion Criteria:~* Women who are lactating, pregnant, or planning to become pregnant~* Patients with a recent history of melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation~* Patients with a known history of photosensitivity disorders~* Photosensitizing medications may be continued throughout of the study at the discretion of the investigator~* Patients with a known history of melanoma or non-melanoma skin cancers~* Concomitant use of tanning beds~* Any reason the investigator feels the patient should not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laser treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perampanel in Focal Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged 18 years or above, including the protected adults with a focal motor status epilepticus, defined by prominent clinically objective focal motor symptoms (clonic, tonic, myoclonic, adversive or oculoclonic), lasting for more than 10 minutes before any treatment or repeated focal motor seizures during this period (≥ 4 seizures in 10 min)~2. The focal motor status continues (or patients show ≥ 2 focal motor seizures) 5 minutes or more after the beginning of administration of benzodiazepines. The delay between administration of benzodiazepines and randomization must not exceed 6 hours.~3. Affiliation to a French social security system (recipient or assign) excluding Aide Médicale Etat (AME)~Exclusion Criteria:~1. Known severe liver (Factor V \<50 %) or kidney (glomerular filtration rate : 15-29 ml/min/1,72 m2) insufficiency~2. Women with known or clinically detected pregnancy~3. Patients with known allergies to perampanel or to any of the excipients mentioned in the summary of product characteristics(SmPC)~4. Patients with postanoxic status~5. Patients in coma (Glasgow\<8)~6. Patients with motor events for which a nonepileptic psychogenic origin is suspected~7. Patients whose status epilepticus is linked to a pathological condition, such as trauma, who needed immediate surgery~8. Known current treatment by perampanel~9. Known galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary diseases)~10. Known participation in another trial with medication and/or previously included in PEPSI study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): immediate enteral administration of Perampanel, 12 mg
- Placebo (Type: PLACEBO_COMPARATOR): immediate enteral administration of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Optical Oximetry in Determining Gastrointestinal Complications After the Hybrid Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of single ventricle and undergoing the hybrid procedure pathway.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regional saturation monitor (Type: None): Patients undergoing surgical repair of hypoplastic left heart syndrome.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 years of age, ≥19 years in Korea, or ≥20 years for subjects in Japan and Taiwan~* Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype limited to:~  1. FL Gr 1, Gr 2, or Gr 3a~ 2. MZL (splenic, nodal, or extra-nodal)~* Subjects with relapsed or refractory disease who received ≥1 prior lines of therapy~* Subjects must have at least one bi-dimensionally measurable lesion \>1.5 cm~* Adequate hematologic parameters at screening unless abnormal values are due to disease~* Adequate renal and hepatic function~* Adequate cardiac function based on ECG and LVEF assessments~Exclusion Criteria:~* Histologically confirmed diagnosis of FL Gr 3b or transformed disease~* Prior therapy with PI3K inhibitors~* Ongoing or history of drug-induced pneumonitis~* Known lymphomatous involvement of the central nervous system~* Tested positive for or active viral infection with hepatitis B or C virus~* Tested positive or active infection with human immunodeficiency virus~* Tested positive, or active infection with human T-cell leukemia virus type 1~* Any uncontrolled clinically significant illness~* History of clinically significant cardiovascular abnormalities such as congestive heart failure~* History of clinically significant gastrointestinal (GI) conditions~* Females who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab plus Zandelisib (Type: EXPERIMENTAL): Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
- Rituximab plus chemotherapy (Type: EXPERIMENTAL): Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men 18 to 85 years of age~* Glaucoma not adequately controlled (IOP \>18 mmHg on maximum tolerated topical therapy) with a single aqueous shunt (AS).~* Best-corrected visual acuity (BCVA) of hand motion (HM) or better in the study eye~Exclusion Criteria:~* Monocular~* Presence of more than one AS in the study eye~* Previous cyclodestruction in the study eye~* Presence of active iris neovascularization in the study eye~* Binocular diplopia~* Presence of scleral buckle in the study eye~* History or scleritis in either eye~* History of scleromalacia in the study eye~* Insufficient conjunctiva to cover AS in the study eye~* IOP cannot be accurately measured with Goldmann applanation, Pneumotonometry, or Tono-Pen in the study eye~* Presence of silicone oil in the study eye~* Presence of retinal detachment in the study eye~* Presence of intraocular or orbital tumor affecting the study eye~* Need for cataract extraction or concurrent procedure at the time of study treatment, except tectonic aqueous shunt revisions for both groups is allowed.~* In the opinion of the investigator, should not be enrolled in this study~* Unwilling or unable to give consent and satisfy requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Second Aqueous Shunt (Type: ACTIVE_COMPARATOR): Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used.
- Transscleral Cyclophotocoagulation (Type: ACTIVE_COMPARATOR): Transscleral Diode Laser Cyclophotocoagulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EpxCogScreen -- A Phone-based Rapid Cognitive Screen (RCS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be \>65 years old~* Patients must have a caregiver or family member who can administer the intervention at home~* Caregivers must be between 18-90 years old~* Caregivers must have a working cellular device with SMS texting capabilities~* Both patients and caregivers must speak English~Exclusion Criteria:~* Patients under the age of 65

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Older adults (Type: None): Older adults, ages 65+

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation Aided Rehabilitation of Gait in Subacute Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Onset of stroke less than 14 days~* First ischemic stroke causing lower limb weakness (MRC score ≤4 in knee extensors) and gait impairment~Exclusion Criteria:~* Contraindications to MRI or TMS~* Other neurological disorders~* Significant somatic or psychiatric disorders~* History of seizures~* Language or cognitive disorders prohibiting participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anodal tDCS with treadmill training (Type: EXPERIMENTAL): Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues